POSITIVE PHASE-II TRIAL OF DIBROMODULCITOL IN PATIENTS WITH METASTATIC MELANOMA REFRACTORY TO DTIC AND A NITROSOUREA

Abstract

Patients (25) with measurable metastatic melanoma refractory to DTIC [dacarbazine] and a nitrosourea were treated with dibromodulcitol (DBD). DBD was administered orally at bedtime at a dose of 100 mg/m2 per day until hematologic toxicity (a .gtoreq. 50% decrease in the wbc [white blood cell] or platelet count) was induced. Five patients experienced clinically useful objective remissions; responding lesions included soft tissue metastases and visceral metastatic disease. DBD may be useful in the treatment of patients with metastatic melanoma and thus joins DTIC and the nitrosoureas as single agents which are active against this malignancy.